Related Experiment Video

Updated: Jun 17, 2025

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model
08:42

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model

Published on: July 3, 2020

4.4K

Targeting the STAT3 pathway with STAT3 degraders

Zhijie Wang1, Xiaotong Liao2, Haiqi He2

  • 1Shenzhen Key Laboratory of Viral Oncology, Ministry of Science and Innovation, Shenzhen Hospital, Southern Medical University, Shenzhen 518100, China; Guangdong Provincial Key Laboratory of New Drug Screening, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.

Trends in Pharmacological Sciences
|August 8, 2024
PubMed

Insights

Signal transducer and activator of transcription 3 (STAT3) degraders offer a promising therapeutic strategy for diseases like cancer. This review explores STAT3 degraders, including PROTACs and natural products, highlighting their mechanisms and potential for drug development.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Signal transducer and activator of transcription 3 (STAT3) is a key therapeutic target for numerous diseases, particularly cancers.
  • STAT3 inhibitors face development challenges, necessitating alternative strategies.
  • STAT3 degraders have emerged as a promising approach to inhibit STAT3 function.

Purpose of the Study:

  • To review recent advancements in STAT3 degraders.
  • To focus on proteolysis targeting chimeras (PROTACs) and small-molecule natural products.
  • To discuss structures, mechanisms, biological activities, opportunities, and challenges of STAT3 degraders.

Main Methods:

  • Literature review of recent advancements in STAT3 degrader research.
  • Analysis of structural and mechanistic properties of STAT3 degraders.
  • Evaluation of biological activities and therapeutic potential.

Main Results:

  • STAT3 degraders, including PROTACs and natural products, demonstrate significant potential in blocking STAT3.
  • Recent research has elucidated diverse structures and mechanisms of action for these degraders.
  • Various STAT3 degraders have shown promising biological activities in preclinical studies.

Conclusions:

  • STAT3 degraders represent a viable and innovative strategy for targeting STAT3 in disease treatment.
  • Further research into the opportunities and challenges will facilitate the development of potent STAT3-targeting drugs.
  • This review provides insights into the discovery and development of novel STAT3 degrader-based therapeutics.
Keywords:
PROTACsSTAT3degradersinhibitorssmall-molecule natural products

More Related Videos

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts11:19

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts

Published on: October 9, 2016

14.9K
Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome07:23

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome

Published on: June 15, 2016

8.5K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.7K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.5K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.4K